Research analysts at Barclays PLC began coverage on shares of Juno Therapeutics, Inc. (NASDAQ:JUNO) in a research report issued on Wednesday, Marketbeat reports. The firm set an “overweight” rating and a $55.00 price target on the biopharmaceutical company’s stock. Barclays PLC’s price target would suggest a potential upside of 31.42% from the stock’s previous close.

Several other research firms also recently weighed in on JUNO. Wedbush raised Juno Therapeutics from a “neutral” rating to an “outperform” rating and set a $42.00 price objective on the stock in a report on Tuesday, August 29th. Wells Fargo & Company reissued an “outperform” rating and set a $54.00 price objective (up previously from $35.00) on shares of Juno Therapeutics in a report on Tuesday, September 5th. Raymond James Financial, Inc. raised Juno Therapeutics from a “market perform” rating to an “outperform” rating and set a $45.00 price objective on the stock in a report on Tuesday, August 29th. Standpoint Research reissued a “reduce” rating on shares of Juno Therapeutics in a report on Thursday, August 31st. Finally, Vetr raised Juno Therapeutics from a “sell” rating to a “hold” rating and set a $28.85 price objective on the stock in a report on Monday, July 10th. Three analysts have rated the stock with a sell rating, six have given a hold rating and nine have issued a buy rating to the stock. Juno Therapeutics currently has an average rating of “Hold” and a consensus target price of $34.88.

Shares of Juno Therapeutics (NASDAQ:JUNO) traded down 1.78% during trading on Wednesday, hitting $41.85. The stock had a trading volume of 1,850,028 shares. The stock’s market capitalization is $4.39 billion. Juno Therapeutics has a one year low of $17.52 and a one year high of $44.60. The stock has a 50 day moving average price of $32.06 and a 200-day moving average price of $26.37.

Juno Therapeutics (NASDAQ:JUNO) last released its quarterly earnings data on Thursday, August 3rd. The biopharmaceutical company reported ($0.96) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.72) by $0.24. Juno Therapeutics had a negative net margin of 354.36% and a negative return on equity of 27.10%. The firm had revenue of $21.30 million for the quarter, compared to analyst estimates of $15.59 million. During the same period last year, the business earned ($0.64) EPS. The company’s revenue was down 22.8% compared to the same quarter last year. On average, equities research analysts predict that Juno Therapeutics will post ($3.12) earnings per share for the current year.

COPYRIGHT VIOLATION WARNING: This news story was originally reported by American Banking News and is the sole property of of American Banking News. If you are accessing this news story on another publication, it was illegally copied and reposted in violation of US and international trademark and copyright law. The legal version of this news story can be accessed at https://www.americanbankingnews.com/2017/09/10/juno-therapeutics-inc-juno-coverage-initiated-at-barclays-plc.html.

In related news, Director Anthony B. Evnin bought 9,000 shares of the business’s stock in a transaction on Tuesday, June 20th. The shares were purchased at an average cost of $24.40 per share, with a total value of $219,600.00. Following the acquisition, the director now owns 66,301 shares of the company’s stock, valued at $1,617,744.40. The purchase was disclosed in a filing with the SEC, which is available through this link. Also, major shareholder Douglas K. Bratton sold 8,000,000 shares of Juno Therapeutics stock in a transaction dated Thursday, July 13th. The stock was sold at an average price of $27.00, for a total value of $216,000,000.00. The disclosure for this sale can be found here. Insiders have sold a total of 8,078,369 shares of company stock worth $218,620,477 over the last ninety days. Company insiders own 15.26% of the company’s stock.

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Utah Retirement Systems lifted its holdings in Juno Therapeutics by 1.8% during the 2nd quarter. Utah Retirement Systems now owns 11,600 shares of the biopharmaceutical company’s stock worth $347,000 after buying an additional 200 shares during the period. State of Wisconsin Investment Board lifted its stake in shares of Juno Therapeutics by 1.7% in the 2nd quarter. State of Wisconsin Investment Board now owns 12,562 shares of the biopharmaceutical company’s stock valued at $375,000 after purchasing an additional 210 shares during the period. The Manufacturers Life Insurance Company lifted its stake in shares of Juno Therapeutics by 7.2% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 3,405 shares of the biopharmaceutical company’s stock valued at $102,000 after purchasing an additional 228 shares during the period. Amalgamated Bank lifted its stake in shares of Juno Therapeutics by 19.0% in the 2nd quarter. Amalgamated Bank now owns 10,900 shares of the biopharmaceutical company’s stock valued at $326,000 after purchasing an additional 1,741 shares during the period. Finally, Evercore Wealth Management LLC lifted its stake in shares of Juno Therapeutics by 6.7% in the 2nd quarter. Evercore Wealth Management LLC now owns 32,062 shares of the biopharmaceutical company’s stock valued at $958,000 after purchasing an additional 2,000 shares during the period. 70.76% of the stock is currently owned by hedge funds and other institutional investors.

Juno Therapeutics Company Profile

Juno Therapeutics, Inc (Juno) is a biopharmaceutical company, which is focused on developing cellular immunotherapies for the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells.

Analyst Recommendations for Juno Therapeutics (NASDAQ:JUNO)

Receive News & Ratings for Juno Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Juno Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.